Kelsey Jakee, Senior Director, Portfolio Strategy & Innovation at TransCelerate BioPharma, argues why advances in clinical R&D won’t solely be dependent on technology. Every few years, the clinical research industry rallies around a new wave of innovation. From decentralised trials and digital biomarkers to AI-driven automation, each wave brings genuine capability and promise. Yet foundational problems like complex protocols, slow enrollment, constrained site capacity and […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!